Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,272 total articles

Sonoco To Report Second Quarter 2026 Results

Sonoco To Report Second Quarter 2026 Results

Sonoco Products Company, a global leader in sustainable packaging, will report its Q2 2026 financial results on July 22, 2026 after market close, followed by a conference call on July 23. The company highlights its strong operational footprint and recent accolades in sustainability and corporate responsibility.

Castor Maritime Inc. Announces Vessel Acquisition

Castor Maritime Inc. Announces Vessel Acquisition

Castor Maritime Inc., a NASDAQ-listed diversified global shipping and energy company, announced the agreement to acquire a modern 2023-built eco-friendly Kamsarmax bulk carrier for $37.5 million. The vessel acquisition, expected to close by the end of the quarter, will expand the company's fleet to 10 vessels, enhancing its dry bulk shipping capaci…

BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026

BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026

BridgeBio Pharma announced that positive primary results from its Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia will be presented at the International Congress of Children's Bone Health (ICCBH) 2026. The company will also share additional research findings on quality of life, early intervention, and disease monitoring …

BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives

BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives

BrainsWay Ltd., a leader in advanced noninvasive brain stimulation technologies, announced significant expansion in favorable medical coverage across the U.S. for its SWIFT Accelerated Deep TMS protocol. Eight major payers and the US Department of Veterans Affairs now cover or support this treatment, impacting over 57 million covered lives. The cov…

Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026

Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026

Medicus Pharma Ltd., a Nasdaq-listed biotech company, announced its participation in the 2026 Bio International Conference to present advancements in its clinical development programs for SkinJect®, an innovative treatment for basal cell carcinoma and Gorlin Syndrome, and Teverelix®, a next-generation GnRH antagonist targeting prostate cancer, acut…

FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations

FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations

Palvella Therapeutics announced that the FDA has granted rolling review for its New Drug Application (NDA) for QTORIN™ rapamycin, aimed at treating microcystic lymphatic malformations, a rare and serious skin disease with no existing FDA-approved therapies. The company expects to complete NDA submission in late 2026, leveraging FDA designations to …

SL Green Realty Corp. to Release Second Quarter 2026 Financial Results After Market Close on July 22, 2026

SL Green Realty Corp. to Release Second Quarter 2026 Financial Results After Market Close on July 22, 2026

SL Green Realty Corp., Manhattan's largest office landlord and a leading REIT, will release its financial results for the second quarter of 2026 after market close on July 22, 2026. The company will host a conference call and webcast on July 23, 2026 to discuss these results, with supplemental financial data made available concurrently on its websi…

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

Nuvectis Pharma has entered an exclusive licensing agreement with Haisco Pharmaceutical Group to acquire ex-China rights to two late-stage clinical compounds: NXP100, a once-daily oral Complement Factor B inhibitor targeting complement-mediated diseases including PNH, IgAN, and LN; and NXP200, a paradox-breaker BRAF inhibitor for BRAF-mutated malig…

Quantum Cyber Issues Letter to Shareholders

Quantum Cyber Issues Letter to Shareholders

Quantum Cyber N.V. updates shareholders on recent strategic developments including high-level engagements with U.S. government officials, a defense and military conference, progress toward acquiring a Connecticut manufacturing facility for drone production, and improved financial strength with over $15 million raised from warrant exercises, positio…

Edible Garden's Pickle Party™ Named "Overall Plant-Based Snack Product of the Year" in 2026 Mindful Awards Program

Edible Garden's Pickle Party™ Named "Overall Plant-Based Snack Product of the Year" in 2026 Mindful Awards Program

Edible Garden AG Incorporated announced that its Pickle Party™ product line was named the 2026 Mindful Award Winner for Overall Plant-Based Snack Product of the Year. The award recognizes innovation, sustainability, product quality, and mindful consumer impact. Pickle Party™ is a unique line of raw, fermented, non-GMO, clean-label pickles and kraut…

GXO to Support Action’s Expansion Across Central and Southern Italy with New Distribution Center in Ferentino

GXO to Support Action’s Expansion Across Central and Southern Italy with New Distribution Center in Ferentino

GXO Logistics announced it will manage operations at a new distribution center in Ferentino, Italy, supporting Action’s expansion across Central and Southern Italy. The facility emphasizes sustainability with a BREEAM Outstanding certification and features energy-efficient technologies. This expansion strengthens GXO's partnership with Action and e…

Lithium Argentina Reports 2026 Annual General Meeting Results

Lithium Argentina Reports 2026 Annual General Meeting Results

Lithium Argentina AG held its 2026 Annual General Meeting where shareholders re-elected eight directors, approved the 2025 financial statements, approved an amended equity incentive plan, and confirmed compensation and auditor appointments. These corporate governance actions position the company for continued operation and oversight of its lithium …

Brunswick Corporation Announces Operational Updates at Lowell Facility

Brunswick Corporation Announces Operational Updates at Lowell Facility

Brunswick Corporation's division, Navico Group, disclosed operational changes at its Lowell, Michigan facility aimed at reducing fixed costs, improving efficiency, and supporting long-term growth. The plan includes expanding insourcing, collaborating more closely with other Brunswick divisions, and utilizing space for Land ‘N’ Sea's distribution op…

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

TScan Therapeutics announced positive initial results from Cohort C of its ongoing ALLOHA Phase 1 study evaluating TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The therapy showed a high rate of complete donor chimerism shortly after infusion and was well tolerated. The company is on tra…

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

NRx Pharmaceuticals received FDA approval for an Expanded Access Protocol allowing compassionate use of NRX-101, a combination of D-cycloserine and lurasidone, to augment Transcranial Magnetic Stimulation (TMS) therapy in treatment-resistant depression patients. The company is concurrently conducting a pivotal clinical trial assessing NRX-101's eff…

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

Regeneron Pharmaceuticals announced that the FDA and EMA have accepted the regulatory submissions for cemdisiran, a potential first siRNA treatment for generalized myasthenia gravis (gMG). The FDA is conducting a Priority Review with a target decision date in November 2026, and a European decision is expected in the second half of 2027. Cemdisiran …

Auddia Announces LT350 Advancement Toward First AI Datacenter Deployment, Engaging Fresh Consulting to Lead Engineering and Development

Auddia Announces LT350 Advancement Toward First AI Datacenter Deployment, Engaging Fresh Consulting to Lead Engineering and Development

Auddia Inc. announced engineering and deployment plans for its LT350 project, which transforms parking lots into distributed AI datacenters via a modular solar canopy platform integrating GPUs and batteries. Fresh Consulting has been engaged to lead the thermal, power, battery, and GPU integration design. This milestone progresses LT350 from concep…

Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus

Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus

Eledon Pharmaceuticals released long-term data from its Phase 2 BESTOW clinical trial demonstrating that tegoprubart, an investigational anti-CD40L antibody, maintained superior kidney function compared to tacrolimus in kidney transplant recipients, with significantly higher eGFR at 18 months and no biopsy-proven acute rejection events after six mo…